Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15777910 | 1.00 | HTR3A (0.53) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL83831 | 1.00 | HTR3A (0.53) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL19459131 | 0.98 | HTR3A (0.52) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL29969490 | 0.98 | HTR3A (0.52) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL19459257 | 0.98 | HTR3A (0.52) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12640684 | 0.90 | HTR3A (0.66) | HTR3A | |
| SCHEMBL1002475 | 0.90 | HTR3A (0.66) | HTR3A | |
| Oxalic Acid SCHEMBL31198885 | 0.90 | JAK3 (0.48) | — | |
| Hydrochloric Acid SCHEMBL15300834 | 0.88 | HTR3A (0.63) | HTR3A | |
| Tartaric Acid SCHEMBL31388195 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113461597-B | Preparation method of nilaparib intermediate | 天津太平洋化学制药有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-111333544-B | Intermediate for synthesizing nilapanib and preparation method thereof | 上海博璞诺科技发展有限公司 | 2023-02-21 | — | — | CN | claimed |
| CN-115108968-A | Production method of 3- (4-bromophenyl) -piperidine | 上药康丽（常州）药业有限公司 | 2022-09-27 | — | — | CN | claimed |
| CN-114507651-A | Recombinant transaminase and application thereof in preparation of chiral intermediate of nilapali | 西南交通大学 | 2022-05-17 | — | — | CN | claimed |
| CN-113461597-A | Preparation method of nilapanib intermediate | 天津太平洋化学制药有限公司 | 2021-10-01 | — | — | CN | claimed |
| CN-111808016-A | Preparation method of nilapanib intermediate (S) -3- (4-bromophenyl) piperidine | 成都正善达生物医药科技有限公司 | 2020-10-23 | — | — | CN | claimed |
| CN-111592467-A | Nilaparib intermediate, preparation method and application thereof, and synthesis method of nilapab | 宁波人健化学制药有限公司 | 2020-08-28 | — | — | CN | claimed |
| CN-111333544-A | Intermediate for synthesizing nilapanib and preparation method thereof | 上海博璞诺科技发展有限公司 | 2020-06-26 | — | — | CN | claimed |
| CN-109456253-B | Method for synthesizing (S) -3- (4-bromophenyl) -piperidine or salt thereof through chiral induction | 上海博璞诺科技发展有限公司 | 2020-04-07 | — | — | CN | claimed |
| CN-110698388-A | Method for industrially producing (S) -3- (4-bromophenyl) piperidine | 暨明医药科技（苏州）有限公司 | 2020-01-17 | — | — | CN | claimed |
| CN-109456253-A | A kind of method of chiral induction synthesis (S) -3- (4- bromophenyl)-piperidines or its salt | 上海博璞诺科技发展有限公司 | 2019-03-12 | — | — | CN | claimed |
| CN-108409638-A | A kind of Niraparib intermediates（S）-3-（4- bromophenyls）The preparation method of piperidines | 东南大学 | 2018-08-17 | — | — | CN | claimed |
| CN-107759506-A | A kind of Buddhist nun draws the preparation method of (4 bromophenyl) piperidines of Pabuk intermediate S 3 | 四川同晟生物医药有限公司 | 2018-03-06 | — | — | CN | claimed |
| CN-119751337-A | Preparation method of high-purity nilaparib intermediate | 南京唯创远医药科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119409624-A | In nilaparib Process for the preparation of intermediates | 泰迩生物医药泰州有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-117964546-B | Preparation method of nilaparib intermediate | 成都硕德药业有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | SANOFI (FR) | 2006-11-09 | — | — | US | disclosed |
| CN-1764650-A | 2, 3, 6-trisubstituted-4-pyrimidone derivatives | MITSUBISHI PHARMA CORP (JP) | 2006-04-26 | — | — | CN | disclosed |
| EP-1608630-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | PSEN1, PSEN2, MAPT | HTR3A 665/4885CYP2D6 3086/4885SLC6A2 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.